Junji Furuse

机构：Kanagawa Prefectural Hospital Organization, Kanagawa Cancer Center · ORCID：0000-0003-0663-6117

发表论文 726 篇 · 总被引 29220 次 · h-index 76

代表论文

• Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC (2025 · Journal of Hepatology · 被引 157)
• Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial (2025 · Journal of Clinical Oncology · 被引 27)
• Systemic therapy for hepatocellular carcinoma, from the early to the advanced stage: a Japanese perspective (2025 · Japanese Journal of Clinical Oncology · 被引 7)
• Tasurgratinib (E7090) for cholangiocarcinoma with fibroblast growth factor receptor 2 fusions/rearrangements: a multicenter, open-label, Phase 2 study (2025 · Japanese Journal of Clinical Oncology · 被引 3)
• Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment (2025 · European Journal of Cancer · 被引 3)
• Long-Term Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in Real-World Clinical Practice (2025 · Cancers · 被引 3)